Patents by Inventor Richard Mark Edwards

Richard Mark Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS
    Publication number: 20240058433
    Abstract: A bacterium of the class Clostridia comprising a heterologous nucleic acid molecule encoding at least one antigen, wherein the bacterium is capable of expressing the antigen in an intracellular compartment of the bacterium during anaerobic cell growth, and wherein at least one antigen is an infectious agent antigen or a tumour antigen.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 22, 2024
    Inventors: Edward Green, Benjamin Michael Bradley, Shison Jiang, Richard Mark Edwards
  • TREATMENT FOR MUCOSITIS
    Publication number: 20090068125
    Abstract: This invention relates to a medicament for protecting human mucosal cells from chemotherapy or radiotherapy induced cell death using formulations comprising adenosine or adenosine analogues as a reversible inhibitor of epithelial cell proliferation. The invention also relates to formulations containing adenosine for the prevention of or reduction in mucositis symptoms.
    Type: Application
    Filed: January 25, 2006
    Publication date: March 12, 2009
    Applicant: HEPTAGEN LTD
    Inventors: Richard Mark Edwards, John Martin Clements
  • Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
    Patent number: 6881828
    Abstract: A hybrid fusion protein comprising a first antigenic amino acid sequence fused to a second amino acid sequence substantially homologous to B2M or a fragment thereof.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: April 19, 2005
    Assignee: Isis Innovations Limited
    Inventors: Richard Mark Edwards, Michael George Hunter
  • Stem cell inhibiting proteins
    Patent number: 6057123
    Abstract: Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: May 2, 2000
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Stewart Craig, Michael George Hunter, Richard Mark Edwards, Lloyd George Czaplewski, Richard James Gilbert
  • Disaggregated mutant human RANTES
    Patent number: 5965697
    Abstract: This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: October 12, 1999
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Lloyd George Czaplewski, Michael George Hunter, Richard Mark Edwards, Keith Martyn Dawson
  • Release and mobilization of haematopoietic cells
    Patent number: 5925568
    Abstract: Stem cell inhibitors such as murine and human macrophage inflammatory protein-1alpha (muMIP-1alpha and huMIP-1alpha/LD78) and their analogues and variants enhance the release and mobilization of haematopoietic cells. This property makes them useful in enhancing responses against infection and in cell harvesting.
    Type: Grant
    Filed: January 16, 1996
    Date of Patent: July 20, 1999
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Michael Berisford Comer, Matthew John McCourt, Lars Michael Wood, Michael George Hunter, Richard Mark Edwards
  • Stem cell inhibiting proteins
    Patent number: 5856301
    Abstract: Proteinaceous molecules with stem cell inhibition activity are analogues of LD78 or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: January 5, 1999
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Stewart Craig, Michael George Hunter, Richard Mark Edwards, Lloyd George Czaplewski, Richard James Gilbert
  • IGF-II analogues
    Patent number: 5854025
    Abstract: Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino acid residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 29, 1998
    Assignee: British Biotech Pharmaceutical Limited
    Inventors: Richard Mark Edwards, Lindsay Bawden
  • IGF-II analogues
    Patent number: 5736363
    Abstract: Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino add residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: April 7, 1998
    Assignee: British Bio-technology Limited
    Inventors: Richard Mark Edwards, Lindsay Bawden